A new diabetes treatment that requires a single daily injection and lasts for 24 hours has been approved for limited prescriptions on the National Health Service. The diabetes drug helps to control diabetes amongst people with type 2 diabetes and is typically prescribed to overweight patients.
Victoza (liraglutide), manufactured by Novo Nordisk, has already been approved in the UK since July 2009. However, the National Institute for Health and Clinical Excellence took some time to review whether the drug is clinically effective and cost effective for type 2 diabetes patients.
NICE concluded that a single daily injection of Liraglutide could be given alongside two anti-diabetic medications. The treatment would specifically be for type 2 diabetes patients also suffering from obesity. As well as helping patients to control and lower blood glucose levels, the diabetes drug also suppresses the appetite of users.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…